Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian P Haen

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
International Journal of Cancer|August 18, 2010
Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablationMelanie Widenmeyer, Yuriy Shebzukhov, Sebastian P Haen, et al.
Vaccines|April 30, 2021
Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient GroupsHans-Georg Rammensee, Cécile Gouttefangeas, Sonja Heidu, et al.
Cancer Research|May 24, 2018
Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell TransformationMarkus W Löffler, Daniel J Kowalewski, Linus Backert, et al.
BMC Medical Genetics|August 17, 2018
First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implicationsMarkus W Löffler, Julia Steinhilber, Franz J Hilke, et al.
Frontiers in Immunology|December 6, 2019
A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal CancerMarkus W Löffler, Bianca Nussbaum, Günter Jäger, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 3, 2017
The immunopeptidomic landscape of ovarian carcinomasHeiko Schuster, Janet K Peper, Hans-Christian Bösmüller, et al.
Genome Medicine|May 2, 2019
Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinomaMarkus W Löffler, Christopher Mohr, Leon Bichmann, et al.
Journal for Immunotherapy of Cancer|November 16, 2019
A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteerHans-Georg Rammensee, Karl-Heinz Wiesmüller, P Anoop Chandran, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
International Journal of Cancer|August 18, 2010
Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablationMelanie Widenmeyer, Yuriy Shebzukhov, Sebastian P Haen, et al.
Vaccines|April 30, 2021
Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient GroupsHans-Georg Rammensee, Cécile Gouttefangeas, Sonja Heidu, et al.
Cancer Research|May 24, 2018
Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell TransformationMarkus W Löffler, Daniel J Kowalewski, Linus Backert, et al.
BMC Medical Genetics|August 17, 2018
First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implicationsMarkus W Löffler, Julia Steinhilber, Franz J Hilke, et al.
Frontiers in Immunology|December 6, 2019
A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal CancerMarkus W Löffler, Bianca Nussbaum, Günter Jäger, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 3, 2017
The immunopeptidomic landscape of ovarian carcinomasHeiko Schuster, Janet K Peper, Hans-Christian Bösmüller, et al.
Genome Medicine|May 2, 2019
Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinomaMarkus W Löffler, Christopher Mohr, Leon Bichmann, et al.
Journal for Immunotherapy of Cancer|November 16, 2019
A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteerHans-Georg Rammensee, Karl-Heinz Wiesmüller, P Anoop Chandran, et al.
Pageof 3